通过p38 MAPK激活,CD2AP缺乏会加剧阿尔茨海默病的表型和病理
Yan-Yan Xue1, Zhe-Sheng Zhang1, Rong-Rong Lin1
1Department of Neurology, The Second Affiliated Hospital, Zhejiang University School of Medicine and Liangzhu Laboratory, 88 Jiefang Road, Hangzhou, 310009, China.
Translational neurodegeneration
|December 19, 2024
概括
缺少CD2关联蛋白 (CD2AP) 通过激活p38 MAPK通路,使阿尔茨海默病 (AD) 恶化,导致病理增加和认知能力下降. 针对CD2AP/p38 MAPK可能提供新的阿尔茨海默氏症治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 阿尔茨海默病 (AD) 是一种流行的神经退行性疾病,其特征是认知能力下降.
- 遗传学研究发现CD2相关蛋白 (CD2AP) 是AD的重要危险因素.
- CD2AP在AD病变发生过程中的确切作用需要进一步阐明.
研究的目的:
- 调查CD2AP在阿尔茨海默病 (AD) 发病过程中的作用.
- 探索将CD2AP与AD联系起来的分子机制.
- 评估CD2AP/p38 MAPK作为AD的潜在治疗点.
主要方法:
- 在大脑中确定CD2AP的时空表达模式.
- 生成并分析了一种具有神经元特定Cd2ap删除的APP/PS1小鼠模型.
- 使用免疫阻塞,免疫光,ELISA,电生理学,行为测试和细胞系研究.
主要成果:
- 在APP/PS1小鼠中,神经元中Cd2ap的缺失加剧了tau病理,突触功能障碍和认知缺陷.
- Cd2ap淘汰激活了p38基激活蛋白激酶 (MAPK) 途径,增加了陶酸化和神经元亡.
- 抑制p38 MAPK改善了AD相关的表型在小鼠中与神经元特异性的Cd2ap删除.
结论:
- 通过p38 MAPK通路,CD2AP缺乏会加剧AD的表型和病理.
- CD2AP/p38 MAPK信号轴是阿尔茨海默病的一个有前途的治疗点.
- 这项研究为CD2AP在AD进展中的作用提供了重要的体内证据.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.CD2AP CD2AP CD2AP CD2AP CD2AP CD2AP CD2AP CD2AP CD2AP CD2AP CD2AP CD2AP CD2AP CD2AP CD2AP在P38 MAPKK中使用.突触损伤是指发生突触损伤.塔乌·塔乌 (Tau Tau) 是一个更多相关视频
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
7.9K
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
42.0K
相关概念视频
01:26Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444
01:22Alzheimer's Disease: Treatment
162
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
162